肝细胞生长因子受体在骨肉瘤中的研究进展  

The role of mesenchymal-epithelial transition factor in osteosarcoma

作　　者：王生淋 王启金 魏鸿翔 翁丹枫[3] 林建华[1] Wang Shenglin;Wang Qijin;Wei Hongxiang;Weng Danfeng;Lin Jianhua(Department of Orthopedics,the First Affiliated Hospital of Fujian Medical University,Fuzhou 350005,China;Department of Orthopedics,the Affiliated Mindong Hospital of Fujian Medical University,Fu'an 355000,China;Department of Pathology,the First Affiliated Hospital of Fujian Medical University,Fuzhou 350005,China)

机构地区：[1]福建医科大学附属第一医院骨科,福州350005 [2]福建医科大学附属闽东医院骨科,福安355000 [3]福建医科大学附属第一医院病理科,福州350005

出　　处：《中华实验外科杂志》2020年第7期1384-1388,共5页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(31571292);福建省发展和改革委员会项目(FGW2014-01)。

摘　　要：骨肉瘤是好发于儿童和青少年的原发恶性骨肿瘤,易复发或转移,且复发或转移的患者预后较差。肝细胞生长因子受体(c-Met)是酪氨酸激酶受体家族成员之一,其激活促进多种肿瘤细胞增殖、上皮-间充质转换(EMT)、转移和抑制肿瘤细胞凋亡。目前关于c-Met在骨肉瘤中的研究较少,其在骨肉瘤中发生发展中的作用尚未完全明确。本文将对c-Met表达及其靶向抑制剂在骨肉瘤中的研究进展作综合性阐述,以期为其在骨肉瘤中的进一步研究阐明方向。Osteosarcoma(OS),most commonly seen in children and adolescents,is a primary malignant bone tumor.Osteosarcoma is prone to relapse or metastasis,and patients with osteosarcoma suffer poor prognoses.Mesenchymal-epithelial transition factor(c-Met)is a member of the tyrosine kinase receptor family,and its activation promotes the proliferation,epithelial-mesenchymal transition,metastasis,and inhibits tumor cell apoptosis in multiple tumors.There are currently limited researches on the role of c-Met in osteosarcoma.The present article aimed to review the role of c-Met expression and c-Met-targeted inhibitors in osteosarcoma,so as to clarify the direction for further research in osteosarcoma.

关 键 词：肝细胞生长因子受体 骨肉瘤 酪氨酸激酶受体家族 

分 类 号：R738.1[医药卫生—肿瘤]